CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection.
1Nephrology, Hannover Medical School, Hannover, Germany
2Pathology, Hannover Medical School, Hannover, Germany
3Radiology, Hannover Medical School, Hannover, Germany
4Laboratory Medicine &
Pathology, University of Alberta, Edmonton, Canada
Meeting: 2017 American Transplant Congress
Abstract number: D38
Session Information
Session Name: Poster Session D: Diagnostics/Biomarkers Session II
Session Type: Poster Session
Date: Tuesday, May 2, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
The majority of kidney allograft rejections are T cell mediated (TCMR). However, it has been shown that in the presence of B-cell clusters the course of rejection is more severe and difficult to control. CXCL-13 is a B-cell chemoattractant and is released systemically. In this study patients with acute cellular rejection and control patients without rejection were tested for circulating CXCL13. In overt rejection serum CXCL13 levels were enhanced significantly. No difference to the control group was detected in borderline rejection. The allograft biopsies of the patients were stained for CD20+ B-cells and different infiltration patterns were identified.
To evaluate further whether CXCL13 release to the circulation correlates with acute allograft rejection a translational mouse model with fully mismatched BALB/c (H2d) kidney graft transplantation into C57B/L6 (B6) recipients was investigated. Isogenic B6 kidney transplantations served as controls. Serum CXCL13 was measured weekly and showed a signifcant increase 6 days after kidney transplantation. In addition, immunohistochemistry revealed Banff 1A, 2B rejection patterns with severe CD3+ cell infiltrates. In addition, B-cell cluster with CD20+ cells could be localized next to renal vessels. By flow cytometry T cell receptor (TCR) positive cells were the majority of infiltrating leukocytes and CD20+ B-cells were also isolated significantly more in allogenic compared to isogenic kidney transplantation. In turn, B-cell depletion was seen in the whole blood of allogenic kidney transplantation mice compared to isogenic kidney transplantation.
Taken together, we present the chemoattractant CXCL-13 as a potential biomarker for B-cell involvement in TCMR rejection indicating patients at risk for more severe clinical course of rejection.
CITATION INFORMATION: Schiffer L, Wiehler F, Daemmrich M, Hueper K, Mengel M, Thorenz A, von Vietinghoff S, Song R, Schiffer M, Gueler F. CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Schiffer L, Wiehler F, Daemmrich M, Hueper K, Mengel M, Thorenz A, Vietinghoff Svon, Song R, Schiffer M, Gueler F. CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/cxcl13-as-a-new-systemic-biomarker-for-b-cell-involvement-in-acute-kidney-allograft-rejection/. Accessed May 13, 2025.« Back to 2017 American Transplant Congress